Cellectis S.a. (CLLS)

$2.09

Market is closed - opens 7 PM, 16 Jul 2024

Performance

  • $2.05
    $2.09
    $2.09
    downward going graph

    1.91%

    Downside

    Day's Volatility :1.91%

    Upside

    0.0%

    downward going graph
  • $0.96
    $3.77
    $2.09
    downward going graph

    53.93%

    Downside

    52 Weeks Volatility :74.46%

    Upside

    44.56%

    downward going graph

Returns

PeriodCellectis S.a.
3 Months
-16.06%
6 Months
-24.55%
1 Year
-5.79%
3 Years
-85.23%

Highlights

Market Capitalization
208.2M
Book Value
$1.26
Earnings Per Share (EPS)
-1.37
PEG Ratio
0.0
Wall Street Target Price
7.0
Profit Margin
0.0%
Operating Margin TTM
-321.56%
Return On Assets TTM
-19.55%
Return On Equity TTM
-78.99%
Revenue TTM
12.1M
Revenue Per Share TTM
0.2
Quarterly Revenue Growth YOY
82.6%
Gross Profit TTM
24.0M
EBITDA
-84.6M
Diluted Eps TTM
-1.37
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.84
EPS Estimate Next Year
-0.8
EPS Estimate Current Quarter
-0.29
EPS Estimate Next Quarter
-0.3

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Cellectis S.a.(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 234.93%

Current $2.09
Target $7.00

Company Financials

FY18Y/Y Change
Revenue
12.7M
↓ 49.46%
Net Income
-78.7M
↓ 20.81%
Net Profit Margin
-618.12%
↓ 223.61%
FY19Y/Y Change
Revenue
15.2M
↑ 19.32%
Net Income
-90.7M
↑ 15.24%
Net Profit Margin
-597.01%
↑ 21.11%
FY20Y/Y Change
Revenue
73.9M
↑ 386.83%
Net Income
-72.6M
↓ 19.98%
Net Profit Margin
-98.14%
↑ 498.87%
FY21Y/Y Change
Revenue
73.9M
↑ 0.0%
Net Income
-86.3M
↑ 18.89%
Net Profit Margin
-116.68%
↓ 18.54%
FY22Y/Y Change
Revenue
19.2M
↓ 74.08%
Net Income
-98.7M
↑ 14.38%
Net Profit Margin
-514.78%
↓ 398.1%
FY23Y/Y Change
Revenue
755.0K
↓ 96.06%
Net Income
-101.1M
↑ 2.4%
Net Profit Margin
-13.4K%
↓ 12870.52%
Q4 FY22Q/Q Change
Revenue
16.0M
↑ 7284.33%
Net Income
-25.7M
↑ 4.16%
Net Profit Margin
-160.4%
↑ 11210.57%
Q1 FY23Q/Q Change
Revenue
139.0K
↓ 99.13%
Net Income
-30.1M
↑ 17.01%
Net Profit Margin
-21.6K%
↓ 21475.57%
Q2 FY23Q/Q Change
Revenue
178.0K
↑ 28.06%
Net Income
-10.6M
↓ 64.59%
Net Profit Margin
-6.0K%
↑ 15653.95%
Q3 FY23Q/Q Change
Revenue
155.0K
↓ 12.92%
Net Income
-17.5M
↑ 64.18%
Net Profit Margin
-11.3K%
↓ 5296.69%
Q4 FY23Q/Q Change
Revenue
283.0K
↑ 82.58%
Net Income
-42.9M
↑ 145.18%
Net Profit Margin
-15.1K%
↓ 3866.87%
Q1 FY24Q/Q Change
Revenue
283.0K
↑ 0.0%
Net Income
-42.9M
↑ 0.0%
Net Profit Margin
-15.1K%
↑ 0.0%
FY18Y/Y Change
Total Assets
500.8M
↑ 50.46%
Total Liabilities
50.6M
↑ 7.64%
FY19Y/Y Change
Total Assets
467.5M
↓ 6.66%
Total Liabilities
112.0M
↑ 121.48%
FY20Y/Y Change
Total Assets
469.5M
↑ 0.43%
Total Liabilities
160.6M
↑ 43.42%
FY21Y/Y Change
Total Assets
382.1M
↓ 18.62%
Total Liabilities
145.6M
↓ 9.35%
FY22Y/Y Change
Total Assets
261.2M
↓ 31.63%
Total Liabilities
135.3M
↓ 7.09%
FY23Y/Y Change
Total Assets
334.3M
↑ 27.97%
Total Liabilities
249.6M
↑ 84.49%
Q4 FY22Q/Q Change
Total Assets
261.2M
↓ 6.57%
Total Liabilities
135.3M
↑ 0.98%
Q1 FY23Q/Q Change
Total Assets
251.4M
↓ 3.75%
Total Liabilities
130.9M
↓ 3.22%
Q2 FY23Q/Q Change
Total Assets
227.7M
↓ 9.44%
Total Liabilities
131.1M
↑ 0.15%
Q3 FY23Q/Q Change
Total Assets
209.7M
↓ 7.89%
Total Liabilities
133.6M
↑ 1.88%
Q4 FY23Q/Q Change
Total Assets
334.3M
↑ 59.4%
Total Liabilities
249.6M
↑ 86.84%
Q1 FY24Q/Q Change
Total Assets
334.3M
↑ 0.0%
Total Liabilities
249.6M
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
-68.1M
↑ 30.21%
Investing Cash Flow
35.6M
↑ 1896.8%
Financing Cash Flow
236.5M
↑ 473.1%
FY19Y/Y Change
Operating Cash Flow
-69.1M
↑ 1.47%
Investing Cash Flow
-35.9M
↓ 200.7%
Financing Cash Flow
-3.9M
↓ 101.63%
FY20Y/Y Change
Operating Cash Flow
-80.3M
↑ 16.08%
Investing Cash Flow
-54.3M
↑ 51.49%
Financing Cash Flow
27.3M
↓ 807.46%
FY21Y/Y Change
Operating Cash Flow
-104.6M
↑ 30.28%
Investing Cash Flow
7.3M
↓ 113.39%
Financing Cash Flow
47.5M
↑ 73.94%
FY22Y/Y Change
Operating Cash Flow
-87.4M
↓ 16.37%
Investing Cash Flow
-2.8M
↓ 137.93%
Financing Cash Flow
1.1M
↓ 97.59%
Q4 FY22Q/Q Change
Operating Cash Flow
-1.2M
↓ 95.32%
Investing Cash Flow
-1.8M
↑ 2831.15%
Financing Cash Flow
-5.0M
↑ 22.38%
Q1 FY23Q/Q Change
Operating Cash Flow
-28.3M
↑ 2221.8%
Investing Cash Flow
-1.8M
↑ 0.0%
Financing Cash Flow
19.8M
↓ 492.3%
Q2 FY23Q/Q Change
Operating Cash Flow
-19.0M
↓ 32.77%
Investing Cash Flow
-1.8M
↑ 0.0%
Financing Cash Flow
19.8M
↑ 0.19%

Technicals Summary

Sell

Neutral

Buy

Cellectis S.a. is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cellectis S.a.
Cellectis S.a.
-2.34%
-24.55%
-5.79%
-85.23%
-86.56%
Moderna, Inc.
Moderna, Inc.
-11.91%
18.91%
-0.91%
-57.59%
759.12%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.51%
15.45%
49.96%
85.53%
262.67%
Novo Nordisk A/s
Novo Nordisk A/s
0.73%
32.95%
75.69%
218.95%
492.58%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.62%
12.2%
37.12%
142.66%
178.64%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cellectis S.a.
Cellectis S.a.
NA
NA
0.0
-0.84
-0.79
-0.2
NA
1.26
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.58
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
32.45
32.45
1.46
44.24
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.59
49.59
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.74
31.74
0.53
17.07
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cellectis S.a.
Cellectis S.a.
Buy
$208.2M
-86.56%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
759.12%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$121.2B
262.67%
32.45
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$639.4B
492.58%
49.59
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.1B
178.64%
31.74
39.46%

Institutional Holdings

  • Long Focus Capital Management, LLC

    4.48%
  • Capital Research & Mgmt Co - Division 3

    1.85%
  • Credit Suisse First Boston (CSFB)

    1.44%
  • Baillie Gifford & Co Limited.

    0.83%
  • Principal Financial Group Inc

    0.42%
  • Macquarie Group Ltd

    0.23%

Company Information

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.

Organization
Cellectis S.a.
Employees
216
CEO
Dr. Andre Choulika Ph.D.
Industry
Health Technology

FAQs